---
schema_version: "secwatch.filing_event.v1"
accession: "0001178670-25-000089"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:10:37.646212+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q2 net product rev $672M (+64% YoY); TTR franchise $544M (+77%); raises FY guidance

## Summary
- Q2 net product revenues $672M, +64% YoY; TTR franchise $544M (+77%) driven by AMVUTTRA sales of $492M.
- GAAP loss from operations $16M vs income $49M in Q2 2024; non-GAAP income from operations $95M.
- Raised FY2025 guidance: TTR revenue to $2.175-2.275B; total net product revenue to $2.65-2.8B (+27% at midpoint).
- ~1,400 ATTR-CM patients on AMVUTTRA as of June 30; approvals secured in EU, UK, Brazil, and Japan.
- Initiated TRITON-CM Phase 3 trial for nucresiran in ATTR-CM; received FDA Fast Track designation.

## SEC filing metadata
- accession: 0001178670-25-000089
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000089/0001178670-25-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000089/alny-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178670-25-000089
- JSON: https://secwatch.observer/filing/0001178670-25-000089.json
- Plain text: https://secwatch.observer/filing/0001178670-25-000089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.